Evidence map›Paper›PMID 41097649›Full record

ReviewCancers2025

Radiomics-Driven Tumor Prognosis Prediction Across Imaging Modalities: Advances in Sampling, Feature Selection, and Multi-Omics Integration.

Mohan Huang, Helen K W Law, Shing Yau Tam

Abstract readReview
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Comparative Dosimetry of Single and HybridDiseases (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mohan HuangSchool of Medical and Health Sciences, Tung Wah College, Hong Kong SAR, China.
Helen K W LawDepartment of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong SAR, China.ORCID 0000-0002-5579-9054
Shing Yau TamSchool of Medical and Health Sciences, Tung Wah College, Hong Kong SAR, China.ORCID 0000-0002-5899-1041

Funding

Hong Kong Polytechnic University WZABTung Wah College Staff Development FundUniversity Grants Committee RMGS230203
6 · The paper itself

Abstract

Radiomics has shown remarkable potential in predicting cancer prognosis by noninvasive and quantitative analysis of tumors through medical imaging. This review summarizes recent advances in the use of radiomics across various cancer types and imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, positron emission tomography (PET), and interventional radiology. Innovative sampling methods, including deep learning-based segmentation, multiregional analysis, and adaptive region of interest (ROI) methods, have contributed to improved model performance. The review examines various feature selection approaches, including least absolute shrinkage and selection operator (LASSO), minimum redundancy maximum relevance (mRMR), and ensemble methods, highlighting their roles in enhancing model robustness. The integration of radiomics with multi-omics data has further boosted predictive accuracy and enriched biological interpretability. Despite these advancements, challenges remain in terms of reproducibility, workflow standardization, clinical validation and acceptance. Future research should prioritize multicenter collaborations, methodological coordination, and clinical translation to fully unlock the prognostic potential of radiomics in oncology.

Indexed as

clinical translationfeature selectionimaging modalitymulti-omicsprognosis predictionradiomicssampling methodstumor prognosis

Identifiers

PMID41097649
PMCPMC12523410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.